Space Filling Fast! Norfolk Island Christmas New Year: Fill & Download for Free

Is this anti Scottish rant meant to influence people in Scotland in some way ???England isn't the only country to come up with a vaccine for Covid19.The questioner forgot to mention that Russia came up withh the vaccine 2 months before Oxford .Was that a mere oversight or ignorance on the Questioner's part ??ScienceMag.orgA nurse gives the Sputnik V experimental COVID-19 vaccine, which new data suggest can successfully protect most people from the disease, to a Moscow man in September.NATALIA KOLESNIKOVA/AFP VIA GETTY IMAGESWith more data on its COVID-19 vaccine, Russian institute offers new evidence of successBy Kai KupferschmidtNov. 24, 2020 , 1:00 PMScience’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.Fever, aches from Pfizer, Moderna jabs aren’t dangerous but may be intense for some‘Incredible milestone for science.’ Pfizer and BioNTech update their promising COVID-19 vaccine resultSee all of our coverage of the coronavirus outbreakThe Sputnik V vaccine, made by the Gamaleya Center for Epidemiology and Microbiology in Moscow, uses adenovirus (Ad) “vectors” to deliver a gene that codes for the surface protein, spike, of SARS-CoV-2, the virus that causes COVID-19. The two-dose scheme begins with an Ad26-spike vaccine and is followed by a booster shot 21 days later that contains Ad5 spike. Gamaleya chose two different adenoviruses because of concerns that immune responses to the same vector could lower the impact of the booster shot.Another adenovirus vaccine, developed by the University of Oxford and AstraZeneca, reported efficacy data yesterday of 70%. It uses the same adenovirus vector for both the prime and the booster shot. “At the moment, the data released today on the Sputnik vaccine looks to be the best in the field of the adeno-vectored vaccines,” says Ian Jones, a virologist at the University of Reading. The Chinese company CanSino Biologics and pharma giant Johnson & Johnson both also have adenovirus vaccines against COVID-19 in efficacy trials.The Russian results presented today are an interim analysis from 18,794 participants 7 days after they received their booster dose. (Only one out of every four received the placebo.) “Whilst the [COVID-19] case numbers remain small, this is highly effective,” Azra Ghani, an infectious disease epidemiologist at Imperial College London, told the Science Media Centre. The ongoing trial will conduct its next interim analysis after 78 confirmed COVID-19 cases. Overall, trial organizers expect to enroll 40,000 participants.The new report allays the concerns raised by many vaccine researchers and public health experts when the Sputnik V team made the earlier efficacy claims, according to Jones. “I think the numbers are now significant and I think they do give credence to what they say,” he says.Dmitriev said the researchers plan to publish results from the trial in an international peer-reviewed journal. Denis Logunov, deputy director at the Gamaleya Center, notes that although side effects including pain at the injection site, headache, and fever had been observed, no serious adverse events had surfaced. “There is nothing unexpected,” he said at the press conference.One benefit of adenovirus vaccines is they can be stored in standard refrigerators, rather than needing freezers. Charlotte Houldcroft, a virologist at the University of Cambridge, cautions that the latest Russian announcement is yet another instance of “science by press release,” but, she adds, “If the figures are as good as they appear, that’s really promising because this needs a standard cold chain to be rolled out rather than an ultracold chain like the RNA vaccines, and that’s a big plus.”“One thing seems to be clear, that this platform works,” Alexey Chumakov, a researcher at the Russian Academy of Medical Science’s Chumakov Institute of Poliomyelitis and Viral Encephalitides in Moscow, wrote in an email. “Of course, with any vaccine, and especially with the ones that have such potential for future revenue flow, as well as political impact, one must be careful in any type of pronouncement, only time and testing will tell.”Dmitriev said partners in India, South Korea, China, and Brazil are producing the vaccine, which could cost less than $10 a shot. Current agreements would allow for the production of 1 billion doses in 2021, with first doses delivered internationally in January.Posted in:HealthCoronavirusdoi:10.1126/science.abf8687Kai KupferschmidtKai is a contributing correspondent for Science magazine based in Berlin, Germany. He is the author of a book about the color blue, published in 2019.TwitterMore from NewsWith global push for COVID-19 vaccines, China aims to win friends and cut dealsAfter dosing mix-up, latest COVID-19 vaccine success comes with big question markIndia needs more transparency in its COVID-19 vaccine trials, critics sayScience'sextensive COVID-19 coverage is free to all readers. To support our nonprofit science journalism, please make a tax-deductible gift today.Got a tip?How to contact the news teamAdvertisementAdvertisementLatest NewsTrendingAtom smasher unearths surprises hidden with 2000-year-old mummyLaser fusion reactor approaches ‘burning plasma’ milestoneMore people are getting COVID-19 twice, suggesting immunity wanes quickly in somePrecise maps of millions of bright quasars show our place in the cosmos as never beforeFever, aches from Pfizer, Moderna jabs aren’t dangerous but may be intense for someMost ReadMore people are getting COVID-19 twice, suggesting immunity wanes quickly in someAnother COVID-19 vaccine success? Candidate may prevent further coronavirus transmission, tooFever, aches from Pfizer, Moderna jabs aren’t dangerous but may be intense for someLaser fusion reactor approaches ‘burning plasma’ milestoneFamed Arecibo telescope, on the brink of collapse, will be dismantledSifterSpace is filled with unexplained lightBy Lucy HicksNov. 19, 2020Breast milk contains coronavirus antibodies, study suggestsBy Lucy HicksNov. 19, 2020Hurricanes are retaining their strength after reaching land, study suggestsBy Lucy HicksNov. 11, 2020Injection of long-acting drug prevents HIV in womenBy Lucy HicksNov. 9, 2020Newly discovered reef is taller than a skyscraperBy Lucy HicksOct. 30, 2020More SifterRead the Latest Issue of Science27 November 2020Vol 370, Issue 6520Table of ContentsASTRONOMYGuiding lightsMEDICINE/DISEASESGrade: IncompleteMEDICINE/DISEASESPublic needs to prep for vaccine side effectsASTRONOMYPotential signs of life on Venus are fading fastMEDICINE/DISEASESStudy homes in on ‘exceptional responders’ to cancer drugsSCIENTIFIC COMMUNITYLaser fusion reactor approaches ‘burning plasma’ milestoneGet Our E-AlertsReceive emails fromScience. See full listScience Table of ContentsScience Daily NewsWeekly News RoundupScience Editor's ChoiceFirst Release NotificationScience Careers Job SeekerCountryCountry*AfghanistanAland IslandsAlbaniaAlgeriaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, The Democratic Republic of theCook IslandsCosta RicaCote D'IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and Mcdonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, The Former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMartiniqueMauritaniaMauritiusMayotteMexicoMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorwayOmanPakistanPalestinianPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalQatarReunionRomaniaRussian FederationRWANDASaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofVietnamVirgin Islands, BritishWallis and FutunaWestern SaharaYemenZambiaZimbabweEmailI also wish to receive emails from AAAS/Scienceand Science advertisers, including information onproducts, services, and special offers which mayinclude but are not limited to news, careerinformation, & upcoming events.Sign up todayRequired fields are indicated by an asterisk (*)About UsJournalsNews from ScienceLeadershipTeam MembersWork at AAASFor AdvertisersAdvertising KitsAwards and PrizesCustom PublishingWebinarsFor AuthorsSubmitInformation for AuthorsEditorial PoliciesFor LibrariansManage Your Institutional SubscriptionInformation for LibrariansRequest a QuoteFAQsRelated SitesAAAS.orgEurekAlert!Science in the ClassroomScience Magazine JapaneseHelpAccess and SubscriptionsOrder a Single IssueReprints and PermissionsContact UsAccessibility© 2020 American Association for the Advancement of Science. All rights Reserved. AAAS is a partner of HINARI, AGORA, OARE, CHORUS, CLOCKSS, CrossRefand COUNTER.Terms of ServicePrivacy PolicyContact AAAS